Disease guided optimization of the respiratory delivery of microparticulate formulations

Expert Opinion on Drug Delivery

Volumn 5, Issue 3, 2008, Pages 269-289

  Xie, Yuanyuan ^a   Zeng, Pengyun ^a   Wiedmann, Timothy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aerosol; Amphotericin B; Asthma; Cystic fibrosis; Fungal infection; Infection; Insulin; Lung cancer; Microparticles; Transplantation; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; CAMPTOTHECIN; CIPROFLOXACIN; CYCLOSPORIN A; ECHINOCANDIN; ETHAMBUTOL; FLUCONAZOLE; GENTAMICIN; HYALURONIC ACID; INSULIN; INTERLEUKIN 2; ISONIAZID; ITRACONAZOLE; LIPOSOME; OLIGOSACCHARIDE; PIPERAZINEDIONE; POLYMER; PYRAZINAMIDE; RECOMBINANT HUMAN INSULIN; RIFAMPICIN; STEROID; TOBRAMYCIN; UNINDEXED DRUG; VORICONAZOLE;

ADRENAL CORTEX DISEASE; AEROSOL; ALLERGIC REACTION; AREA UNDER THE CURVE; ASTHMA; BIOAVAILABILITY; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSPHAGIA; DYSPNEA; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LOWER RESPIRATORY TRACT; LUNG CANCER; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEBULIZER; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OROPHARYNX CANDIDIASIS; PHYSICAL CHEMISTRY; PNEUMONIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SUSTAINED RELEASE PREPARATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

ANIMALS; BRONCHODILATOR AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES; MICROSPHERES; PARTICLE SIZE; RESPIRATORY SYSTEM;

EID: 41449106353     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.3.269     Document Type: Review

References (178)

1. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58(9-10):1030-60
2. Sakagami M, Byron PR. Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet 2005;44(3):263-77
3. Videira MA, Gano L, Santos C, Neves M, Almeida AJ. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J Microencapsul 2006;23(8):855-62
4. Hagerman JK, Hancock KE, Klepser ME. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006;3(1):71-86
5. Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res 2007;24(3):411-37
6. Geller DE, Pitlick WH, Nardella PA, et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-26
7. Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994;34(3):255-9
8. Touw DJ, Jacobs FA, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41(1):184-7
9. Mukhopadhyay S, Staddon GE, Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88(3):203-11
10. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136(6):1445-9
11. Poyner EA, Alpar HO, Almeida AJ, et al. A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J Control Rel 1995;35(1):41-8
12. Schreier H, Gonzales-Rothi RJ, Stecenko AA. Pulmonary delivery of liposomes. J Control Release 1993;24:209-23
13. Farr SJ, Kellaway IW, Parry-Jones DR, Woolfrey SG. Technetium-99m as a marker of liposomal deposition and clearance in the human lung. Int J Pharm (Kidlington) 1985;26(3):303-16
14. Beaulac C, Sachetelli S, Lagace J. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J Drug Target 1999;7(1):33-41
15. Sachetelli S, Beaulac C, Riffon R, Lagace J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs. Biochim Biophys Acta 1999;1428(2-3):334-40
16. Marier JF, Brazier JL, Lavigne J, Ducharme MP. Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003;52(2):247-52
17. Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest 2003;124(1):360-6
18. Pilcer C, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006
19. Pandey, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005;55:430-5
20. De Souza MV. Current status and future prospects for new therapies for pulmonary tuberculosis. Curt Opin Pulm Med 2006;12:167-71
21. Douglas JG, Mcleod MJ. Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 1999;37(2):127-46
22. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003;47(7):2118-24
23. Bain DF, Munday DL, Smith A. Modulation of rifampicin release from spray-dried microspheres using combinations of poly-(DL-lactide). J Microencapsul 1999;16(3):369-85
24. Zhang W, Jiang X, Hu J, Fu C. Rifampicin polylactic acid microspheres for lung targeting. J Microencapsul 2000;17(6):785-8
25. O'hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000;17(8):955-61
26. Suarez S, O'Hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 2001;48(3):431-4
27. Suarez S, O'Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001;18(9):1315-9
28. Garcia-Contreras L, Sethuraman V, Kazantseva M, et al. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother 2006;58(5):980-6
29. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 2001;18(10):1405-10
30. Sharma R, Muttil P, Yadav AB, et al. Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother 2007;59(3):499-506
31. Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003;52(6):981-6
32. Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26(4):298-303
33. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother 2004;54(4):761-6
34. Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006;13(4):287-94
35. Kurunov IUN, Ursov IG, Krasnov VA, et al. Effectiveness of liposomal antibacterial drugs in the inhalation therapy of experimental tuberculosis. Probl Tuberk 1995;7(1):38-40
36. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 2004;24(1):93-4
37. Vyas SP, Kannan ME, Jain S, et al. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 2004;269(1):37-49
38. Justo OR, Moraes AM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv 2003;10(3):201-7
39. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb) 2005;85(4):227-34
40. Tsapis N, Bennett D, O'Driscoll K, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb) 2003;83(6):379-85
41. Drew. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006;27(Suppl 1):36-44
42. Cocogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41(2):259-61
43. Physicians' Desk Reference (ed.); 2006
44. Allen SD, Sorensen KN, Nijdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34(6):1001-13
45. Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations - Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis. Antimicrob Agents Chemother 2004;48(3):1047-50
46. Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000;52(6):619-27
47. Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001;48(1):89-95
48. Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296(1-2):12-25
49. Lambros MP, Bourne DW, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997;86(9):1066-9
50. Niki Y, Bernard EM, Schmitt HJ, et al. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990;34(1):29-32
51. Sschwartz, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolong neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93:3654-61
52. Marra F, Partovi N, Wasan KM, et al. Amphotericin B disposition after aerosol inhalation in lung transplant recipients. Ann Pharmacother 2002;36(1):46-51
53. Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77(2):232-7
54. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72(3):545-8
55. McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions to a murine model. Pharm Res 2006;23(5):901-11
56. Vaughn JM, McConville JT, Burgess D, et al. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006;63(2):95-102
57. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276(5320):1868-71
58. Sakagami M. Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacokinetics. Clin Pharmacokinet 2004;43(8):539-52
59. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999;16(11):1735-42
60. Kawashima Y, Yamamoto H, Takeuchi H, et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Rel 1999;62(1-2):279-87
61. Blair J, Coghlan D, Langer E et al. Sustained delivery of insulin via the lung using Solidose technology. Dalby RN, Byron PR, Peart J, Farr SJ, editor. Raleigh, NC: Davis Horwood International Publishing; 2002. p. 411-3
62. Garcia-Contreras L, Morcol T, Bell SJ, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci 2003;5(2):E9
63. Steiner S, Pfutzner A, Wilson BR, et al. Technosphere/Insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110(1):17-21
64. Surendrakumar K, Martyn GP, Hodgers EC, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Rel 2003;91(3):385-94
65. Uugaro F, De Rosa G, Miro A, et al. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006;28(5):423-32
66. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Rel 2006;113(1):9-14
67. Karathanasis E, Bhavane R, Annapragada AV. Triggered release of inhaled insulin from the agglomerated vesicles: pharmacodynamic studies in rats. J Control Rel 2006;113(2):117-27
68. Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 2006;58(9-10):1119-27
69. Sommerer C, Konstandin M, Dengler T, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006;82(10):1280-5
70. Dowling RD, Zenati M, Burckart GJ, et al. Aerosolized cyclosporine as single-agent immunotherapy in canine lung allografts. Surgery 1990;108(2):198-204; discussion 204-195
71. Keenan RJ, Duncan AJ, Yousem SA, et al. Improved immunosuppression with aerosolized cyclosporine in experimental pulmonary transplantation. Transplantation 1992;53(1):20-5
72. Zenati M, Duncan AJ, Burckart GJ, et al. Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur J Cardiothorac Surg 1991;5(5):266-71; discussion 272
73. Koshkina NV, Golunski E, Roberts LE, et al. Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice. J Aerosol Med 2004;17(1):7-14
74. O'Riordan TG, Iacono A, Keenan RJ, et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995;151(2 Pt 1):516-21
75. Iacono AT, Smaldone GC, Keenan RJ, et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 1997;155(5):1690-8
76. Knoop C, Vervier I, Thiry P, et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003;76(4):683-8
77. Corcoran TE, Smaldone GC, Dauber JH, et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 2004;23(3):378-83
78. Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996;153(4 Pt 1):1451-5
79. Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004;23(3):384-90
80. Lai YL, Mehta RC, Thacker AA, et al. Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres. Pharm Res 1993;10(1):119-25
81. Ben-Jebria A, Chen D, Eskew ML, et al. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 1999;16(4):555-61
82. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000;17(2):168-74
83. Vidgren M, Waldrep JC, Arppe J, et al. A study of 99mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int J Pharm (Amsterdam) 1995;115(2):209-16
84. Huang YC, Yeh MK, Cheng SN, Chiang CH. The characteristics of betamethasone-loaded chitosan microparticles by spray-drying method. J Microencapsul 2003;20(4):459-72
85. Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J Control Rel 2001;77(1-2):117-29
86. Bandi N, Ayalasomayajula SP, Dhanda DS, et al. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol 2005;57(7):851-60
87. American Cancer Society. Available from: http://www.cancer.org
88. Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention, Volume 1: Promising Cancer Chemopreventive Agents. (ed.) New Jersey: Humans Press; 2004
89. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5(9):2316-23
90. Knight V, Kleinerman ES, Waldrep JC, et al. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann NY Acad Sci 2000;922:151-63
91. Knight V, Koshkina NV, Golunski E, et al. Cyclosporin a aerosol improves the anticancer effect of Paclitaxel aerosol in mice. Trans Am Clin Climatol Assoc 2004;115:395-404
92. Knight V, Koshkina NV, Waldrep JC, et al. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother Pharmacol 1999;44(3):177-86
93. Hitzman CJ, Wattenberg LW, Wiedmann TS. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J Pharm Sci 2006;95(6):1196-211
94. Anderson PM, Katsanis E, Leonard AS, et al. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 1990;50(6):1853-6
95. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996;2(4):721-34
96. Khanna C, Waldrep JC, Anderson PM, et al. Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 1997;49(10):960-71
97. Khanna C, Vail DM. Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers. Curr Cancer Drug Targets 2003;3(4):265-73
98. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a Phase I clinical trial. Anticancer Drugs 2000;11(7):555-63
99. Ten RM, Anderson PM, Zein NN, et al. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002;2(2-3):333-44
100. Koshkina NV, Waldrep JC, Roberts LE, et al. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001;7(10):3258-62
101. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999;5(9):2653-9
102. Koshkina NV, Knight V, Gilbert BE, et al. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 2001;47(5):451-6
103. Hitzman CJ, Elmquist WF, Wartenberg LW, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci 2006;95(5):1114-26
104. Hitzman CJ, Elmquist WF, Wiedmann TS. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci 2006;95(5):1127-43
105. Hitzman CJ, Wiedmann TS, Dai H, Elmquist WF. Measurement of drug release from microcarriers by microdialysis. J Pharm Sci 2005;94(7):1456-66
106. Tatsumura T, Kroyama S, Tsujimoto M, et al. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68(6):1146-9
107. McIntire GL, Bacon ER, Toner JL, et al. Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to lung draining lymph nodes in dogs. J Pharm Sci 1998;87(11):1466-70
108. Grassi C, Ginesu F, Pozzi E, et al. Once-daily tobramycin therapy in lower respiratory tract infections. J Chemother 1995;7(4):371-9
109. Van't Veen A, Gommers D, Verbrugge SJ, et al. Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle. Br J Pharmacol 1999;126(5):1091-6
110. Wichert BV, Gonzalez-Rothi RJ, Straub LE, et al. Amikacin liposomes characterization aerosolization and in vitro activity against mycobacterium-avium-intracellulare in alveolar macrophage. Int J Pharm (Kidlington) 1992;78(2-3):227-36
111. Schreier H, McNicol KJ, Ausborn M, et al. Pulmonary delivery of amikacin liposomes and acute liposome toxicity in the sheep. Int J Pharm (Amsterdam) 1992;87(1-3):183-93
112. Sweeney LG, Wang Z, Loebenberg R, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305(1-2):180-5
113. McIlleron H, Wash P, Burger A, et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006;50(4):1170-7
114. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1997;1334(2-3):161-72
115. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 1997;41(6):1211-4
116. Pandey R, Sharma S, Khuller GK. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 2004;23(4):414-5
117. Liu ZZ, Guo XD, Straub LE, et al. Lipophilic N-acylpyrazinamide derivatives: synthesis, physicochemical characterization, liposome incorporation, and in vitro activity against Mycobacterium avium-intracellulare. Drug Des Discov 1991;8(1):57-67
118. Kurunov IUN, Nikolin VP, Kaledin VI, et al. Effectiveness of antibacterial preparations incorporated into liposomes in the treatment of experimental tuberculosis. Probl Tuberk 1982;(10):54-8
119. Kurunov IUN, Kaledin VI, Popova NA, Panteleeva AG. Effectiveness of a liposomal form of rifampicin in the treatment of experimental tuberculosis in mice. Probl Tuberk 1992;1-2:13-5
120. Dutt M, Khuller GK. Liposomes and PLG microparticles as sustained release antitubercular drug carriers- an in vitro-in vivo study. Int J Antimicrob Agents 2001;18(3):245-52
121. Tomoda K, Kojima S, Kajimoto M, et al. Effects of pulmonary surfactant system on rifampicin release from rifampicin-loaded PLGA microspheres. Colloids Surf B Biointerfaces 2005;45(1):1-6
122. Zhou H, Zhang Y, Biggs DL, et al. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages. J Control Rel 2005;107(2):288-99
123. Liu JH, Zhang LS, Liu ZG, et al. Study on the characteristics of mutation on Mycobacterium tuberculosis rifampicin-resistance gene. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27(11):973-6
124. Gilbert BE, Wyde PR, Wilson SZ. Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother 1992;36(7):1466-71
125. Gilbert BE, Wyde PR, Lopez-Berestein G, Wilson SZ. Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob Agents Chemother 1994;38(2):356-9
126. Shah SP, Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv 2004;11(4):247-53
127. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996;9(1):111-22
128. Kim JC, Kim JD. Preparation by spray drying of amphotericin B-phospholipid composite particles and their anticellular activity. Drug Deliv 2001;8(3):143-7
129. Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6(11):2765-73
130. Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother 2006;58(2):466-9
131. Liu FY, Shao Z, Koldsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10(2):228-32
132. VanBever R, Ben-Jebria A, Mintzes JD, et al. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res 1999;48(4):178-85
133. Gilbert BE, Knight C, Alvarez FG, et al. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997;156(6):1789-93
134. Waldrep JC, Scherer PW, Keyhani K, Knight V. Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition. Int J Pharm (Amsterdam) 1993;97(1-3):205-12
135. Waldrep JC, Arppe J, Jansa KA, Knight V. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm (Amsterdam) 1997;152(1):27-36
136. Kawashima Y, Serigano T, Hino T, et al. Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose. Pharm Res 1998;15(11):1753-9
137. Pettenazzo A, Jobe A, Ikegami M, et al. Clearance of phosphatidylcholine and cholesterol from liposomes, liposomes loaded with metaproterenol, and rabbit surfactant from adult rabbit lungs. Am Rev Respir Dis 1989;139(3):752-8
138. McCalden TA, Abra RA, Mihalko PJ. Bronchodilator effects of some liposome formulations of metaproterenol sulfate in guinea pigs. Proc West Pharmacol Soc 1988;31:129-32
139. McCalden TA, Porter J, Kamarei A. Aerosol delivery of liposome metaproterenol sulfate. Proc West Pharmacol Soc 1990;33:171-3
140. McCalden TA, Radhakrishnan R. A comparative study of the bronchodilator effect and duration of action of liposome encapsulated beta-2 adrenergic agonists in the guinea-pig. Pulm Pharmacol 1991;4(3):140-5
141. Taylor KM, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res 1989;6(7):633-6
142. Fielding RM, Abra RM. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm Res 1992;9(2):220-3
143. Sebti T, Pilcer G, Van Gansbeke B, et al. Pharmacoscintigraphic evaluation of lipid dry powder budesonide formulations for inhalation. Eur J Pharm Biopharm 2006;64(1):26-32
144. Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994;105(1):106-10
145. Waldrep JC, Gilbert BE, Knight CM, et al. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest 1997;111(2):316-23
146. Forsgren PE, Modig JA, Dahlback CM, Axelsson BI. Prophylactic treatment with an aerosolized corticosteroid liposome in a porcine model of early ARDS induced by endotoxaemia. Acta Chir Scand 1990;156(6-7):423-31
147. McCullough HN, Juliano RL. Organ-selective action of an antitumor drug: pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J Natl Cancer Inst 1979;63(3):727-31
148. Juliano RL, McCullough HN. Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Ther 1980;214(2):381-7
149. Sone S, Tachibana K, Shono M, et al. Potential value of liposomes containing muramyl dipeptide for augmenting the tumoricidal activity of human alveolar macrophages. J Biol Response Mod 1984;3(2):185-94
150. Lorenz J, Wilhelm K, Kessler M, et al. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 1996;2(7):1115-22
151. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997;79(7):1409-21
152. Rao JN, Clark SC, Aali S, et al. Improvements in lung compliance after pulmonary transplantation: correlation with interleukin 8 expression. Eur J Cardiothorac Surg 2003;23(4):497-502
153. Rohrmann K, Schleypen J, Adam C, et al. Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy. Urologe A 2004;43(10):1271-4
154. Koshkina NV, Gilbert BE, Waldrep JC, et al. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 1999;44(3):187-92
155. Verschraegen CF, Gilbert BE, Huaringa AJ, et al. Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann NY Acad Sci 2000;922:352-4
156. Koshkina NV, Waldrep JC, Knight V. Camptothecins and lung cancer: improved delivery systems by aerosol. Curr Cancer Drug Targets 2003;3(4):251-64
157. Lawson KA, Anderson K, Snyder RM, et al. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004;54(5):421-31
158. Parthasarathy R, Gilbert B, Mehta K. Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemother Pharmacol 1999;43(4):277-83
159. Wang Z, Chen HT, Roa W, Finlay W. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharm Sci 2003;6(1):95-100
160. Jin H, Kim TH, Hwartg SK, et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther 2006;5(4):1041-9
161. Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 2006;319(1-2):155-61
162. Tian Y, Klegerman ME, Hickey AJ. Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs. PDA J Pharm Sci Technol 2004;58(5):266-75
163. Wittgen BP, Kunst PW, Van Der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007;13(8):2414-21
164. Halme M, Maasilta P, Repo H, et al. Inhaled recombinant interferon gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and morsocytes. Int J Radiat Oncol Biol Phys 1995;31(1):93-101
165. Barker SA, Taylor KMG, Short MD. The deposition and clearance of liposome entrapped 99mTc-DTPA ion the human respiratory tract. Int J Pharm (Amsterdam) 1994;102(1-3):159-65
166. Gervelas C, Serandour AL, Geiger S, et al. Direct lung delivery of a dry powder formulation of DTPA with improved aerosolization properties: effect on lung and systemic decorporation of plutonium. J Control Rel 2007;118(1):78-86
167. Wang J, Ben-Jebria A, Edwards DA. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 1999;12(1):27-36
168. Morimoto K, Katsumata H, Yabuta T, et al. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000;52(6):611-7
169. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res 2004;21(7):1119-26
170. Bot AI, Tarara TE, Smith DJ, et al. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000;17(3):275-83
171. Bot AI, Smith DJ, Bot S, et al. Receptor-mediated targeting of spray-dried lipid particles coformulated with immunoglobulin and loaded with a prototype vaccine. Pharm Res 2001;18(7):971-9
172. Dellamary L, Smith DJ, Bloom A, et al. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J Control Rel 2004;95(3):489-500
173. Wyde PR, Wilson SZ, Kramer MJ, et al. Pulmonary deposition and clearance of aerosolized interferon. Antimicrob Agents Chemother 1984;25(6):729-34
174. Buckley BJ, Tanswell AK, Freeman BA. Liposome-mediated augmentation of catalase in alveolar type II cells protects against H2O2 injury. J Appl Physiol 1987;63(1):359-67
175. Jurima-Romet M, Barber RF, Demeester J, Shek PN. Distribution studies of liposome-encapsulated glutathione administered to the lung. Int J Pharm (Kidlington) 1990;63(3):227-36
176. Jurima-Romet M, Shek PN. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J Pharm Pharmacol 1991;43(1):6-10
177. Debs RJ, Straubinger RM, Brunette EN, et al. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. Am Rev Respir Dis 1987;135(3):731-7
178. Wyde PR, Six HR, Wilson SZ, et al. Activity against rhinoviruses,